Events

European Partnership on Rare Diseases (ERDERA) - Launch Event
OCT
Mon
28
14:00 - 16:30

This was 1 year ago

Location

Online

Programmes
Health

The European Partnership on Rare Diseases (ERDERA) organises an open session to present the new partnership to a broad audience of interested stakeholders.

The list of speakers includes, among others: 

  • Irene Norstedt, Director, People Directorate DG RTD, European Commission 
  • Arjon Van Hengel, Deputy Head of Unit, Health Innovations & Ecosystems, European Commission 
  • Virginie Bros-Facer, CEO, EURORDIS 
  • Prof. Guillaume Canaud, Hôpital Necker-Enfants malades AP-HP, France 
  • James Levine, President, Fondation Ipsen 
  • Daria Julkowska, ERDERA Scientific Coordinator, INSERM 

More information about the event and the link to register on the ERDERA website.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.